UNCY
Unicycive Therapeutics, Inc.
There isn't enough reported data to score UNCY yet.
UNCY Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
UNCY's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNCY PE Valuation
UNCY has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 8.2x next year's earnings.
UNCY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect UNCY to return to profit, with revenue growing. However, they disagree widely on these estimates.
UNCY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.44 | — |
| Q3 2023 | -$17.40 | -$6.96 |
| Q2 2023 | -$19.80 | -$9.36 |
| Q1 2023 | -$19.30 | -$9.96 |
| Q4 2022 | -$12.00 | -$4.43 |
| Q3 2022 | -$10.44 | -$4.23 |
| Q2 2022 | -$10.44 | -$7.47 |
| Q1 2022 | -$9.34 | -$7.45 |
| Q4 2021 | -$7.57 | -$6.08 |
UNCY is still losing money, but far less than before: $1.70 per share over the past year, against $19.80 at its worst in mid-2023.
UNCY Quarterly Revenue
UNCY's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -584% | N/A |
UNCY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.6M | +$823K |
| Q1 2026 | -$6.2M | +$2.7M |
| Q4 2025 | -$8M | -$1.5M |
| Q3 2025 | -$6M | +$3.3M |
| Q2 2025 | -$8.4M | -$2.1M |
| Q1 2025 | -$8.9M | -$2.5M |
| Q4 2024 | -$6.6M | -$2.1M |
| Q3 2024 | -$9.3M | -$4.9M |
UNCY has burned cash in almost every quarter: −$28M over the past year, against −$33M the year before.
UNCY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +3M shares |
| 1 year | +117% | +14.5M shares |
| 3 years | +1687% | +25.4M shares |
| 5 years | +1665% | +25.4M shares |
UNCY has 27M diluted shares, up 117% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
UNCY Net Leverage
UNCY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNCY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 12.2 | Oversold |
UNCY's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
UNCY PE vs Healthcare Sector
UNCY has no meaningful PE right now: it lost money over the past year.
UNCY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.90 | 6.7% below |
| 20 week MA | $4.73 | 23% below |
| 50 week MA | $5.96 | 39% below |
| 100 week MA | $5.75 | 37% below |
| 200 week MA | $7.50 | 51% below |
UNCY is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
UNCY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $32.0 | $20.9 | -35% |
| 2022 | $20.9 | $6.89 | -67% |
| 2023 | $6.89 | $8.68 | +26% |
| 2024 | $8.68 | $8.00 | -7.8% |
| 2025 | $8.00 | $6.07 | -24% |
| 2026 YTD | $6.07 | $3.64 | -40% |
UNCY has finished lower in four of the last five years. It's down 40% so far in 2026.